Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism

Pharmacological studies implicate the blockade of adenosine receptorsas an effective strategy for reducing Parkinson’s disease (PD) symptoms. The objective of this study is to elucidate the possible protective effects of ZM241385 and 8-cyclopentyl-1, 3-dipropylxanthine, two selective A2A and A1 receptor antagonists, on a rotenone rat model of PD. Rats were split into four groups: vehicle control (1 ml/kg/48 h), rotenone (1.5 mg/kg/48 h, s.c.), ZM241385 (3.3 mg/kg/day, i.p) and 8-cyclopentyl-1, 3-dipropylxanthine (5 mg/kg/day, i.p). After that, animals were subjected to behavioral (stride length and grid walking) and biochemical (measuring concentration of dopamine levels using high performance liquid chromatography, HPLC). In the rotenone group, rats displayed a reduced motor activity and disturbed movement coordination in the behavioral tests and a decreased dopamine concentration as foundby HPLC. The effect of rotenone was partially prevented in the ZM241385 group, but not with 8-cyclopentyl-1,3-dipropylxanthine administration. The administration of ZM241385 improved motor function and movement coordination (partial increase of stride length and partial decrease in the number of foot slips) and an increase in dopamine concentration in the rotenone-injected rats. However, the 8-cyclopentyl-1,3-dipropylxanthine and rotenone groups were not significantly different. These results indicate that selective A2A receptor blockade by ZM241385, but not A1 receptor blockadeby 8-cyclopentyl-1,3-dipropylxanthine, may treat PD motor symptoms. This reinforces the potential use of A2A receptor antagonists as a treatment strategy for PD patients

Effects of administration of 10 nm or 50 nm gold nanoparticles (AuNPs) on blood profile, liver and kidney functions in male albino rats

This work aimed to investigate the effect of acute and chronic administration of gold nanoparticles (GNPs) on liver and kidney functions, blood glucose concentration, lipid profile, and haematological parameters in male albino rats. Two experiments were conducted. In acute study: Fifty-four adult mature male rats were randomly assigned into three equal groups (18 per group). Group 1 (control group): in which rats were received intramuscular (i.m) injection of 1 ml normal saline 0.9%. Group 2 (50 nm GNPs group): rats were i.m. injected with a single dose of 75 µg 50 nm GNPs/kg body weight (bwt). In Group 3 (10 nm GNPs group): rats were i.m. injected with a single dose of 75 µg 10 nm GNPs/kg bwt. In chronic study: Eighteen adult male rats were randomly divided into three equal groups (6 per group). Group І (control): rats were intramuscular (i.m) repeatedly injected with 1 ml normal saline 0.9% once/week 5 for weeks. Group 2 (50 nm GNPs): rats were i.m. injected with once/week with a dose of 75 µg 50 nm GNPs/kg bwt) for 5 weeks. In Group 3 (10 nm GNPs): male rats were i.m. injected with once/week with a dose of 75 µg 50 nm GNPs/kg bwt for 5 weeks, followed by 3 weeks washout period for all groups. Blood was collected at 3, 7, and 60 days in acute experiment, while, they were collected only before and after 2 months in chronic experiment. Acute and chronic administration of GNPs (10 or 50 nm size) in male albino rats induced no significant alterations for liver and kidney functions, lipid profile parameters and different haematological parameters at days 3 and 60 of the study. However, on day-7 post-treatment, GNPs-treated rats showed significantly (P <0.05) higher serum ALT, AST, ALP, urea, creatinine, glucose, and different lipid profile and decreased HDL level. Chronic administration of 10 nm or 50 nm GNPs significantly (P <0.05) decreased serum glucose levels. In conclusion acute or chronic administration of 10 nm or 50 nm GNPs could alter the liver, kidney functions and blood profile on day 7 post-treatment, however, these values returned to the normal levels on day 60 post- injection. Also, the chronic administration of GNPs induced a hypoglycemic effect in male albino rats

The impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve: a systematic review

Background Benign nonendometriotic ovarian cysts are very common and often require surgical excision. However, there has been a growing concern over the possible damaging effect of this surgery on ovarian reserve. Objective The aim of this metaanalysis was to investigate the impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve as determined by serum anti-Müllerian hormone level. Data Sources MEDLINE, Scopus, ScienceDirect, and Embase were searched electronically. Study Design All prospective and retrospective cohort studies as well as randomized trials that analyzed changes of serum anti-Müllerian hormone concentrations after excision of benign nonendometriotic cysts were eligible. Twenty-five studies were identified, of which 10 were included in this analysis. Data Extraction Two reviewers performed the data extraction independently. Results A pooled analysis of 367 patients showed a statistically significant decline in serum anti-Müllerian hormone concentration after ovarian cystectomy (weighted mean difference, –1.14 ng/mL; 95% confidence interval, –1.36 to –0.92; I2 = 43%). Subgroup analysis including studies with a 3-month follow-up, studies using Gen II anti-Müllerian hormone assay and studies using IOT anti-Müllerian hormone assay improved heterogeneity and still showed significant postoperative decline of circulating anti-Müllerian hormone (weighted mean difference, –1.44 [95% confidence interval, –1.71 to –1.1; I2 = 0%], –0.88 [95% confidence interval, –1.71 to –0.04; I2 = 0%], and –1.56 [95% confidence interval, –2.44 to –0.69; I2 = 22%], respectively). Sensitivity analysis including studies with low risk of bias and excluding studies with possible confounding factors still showed a significant decline in circulating anti-Müllerian hormone. Conclusion Excision of benign nonendometriotic ovarian cyst(s) seems to result in a marked reduction of circulating anti-Müllerian hormone. It remains to be established whether this reflects a real compromise to ovarian reserve

Effects of administration of 10 nm or 50 nm gold nanoparticles (AuNPs) on blood profile, liver and kidney functions in male albino rats

486-493This work aimed to investigate the effect of acute and chronic administration of gold nanoparticles (GNPs) on liver and kidney functions, blood glucose concentration, lipid profile, and haematological parameters in male albino rats. Two experiments were conducted. In acute study: Fifty-four adult mature male rats were randomly assigned into three equal groups  (18  per  group).   Group   1   (control   group):  in   which  rats   were  received   intramuscular   (i.m)   injection  of 1 ml normal saline 0.9%. Group 2 (50 nm GNPs group): rats were i.m. injected with a single dose of 75 µg 50 nm GNPs/kg body weight (bwt). In Group 3 (10 nm GNPs group): rats were i.m. injected with a single dose of 75 µg 10 nm GNPs/kg bwt. In chronic study: Eighteen adult male rats were randomly divided into three equal groups (6 per group). Group І (control): rats were intramuscular (i.m) repeatedly injected with 1 ml normal saline 0.9% once/week 5 for weeks. Group 2 (50 nm GNPs): rats were i.m. injected with once/week with a dose of 75 µg 50 nm GNPs/kg bwt) for 5 weeks. In Group 3 (10 nm GNPs): male rats were i.m. injected with once/week with a dose of 75 µg 50 nm GNPs/kg bwt for 5 weeks, followed by 3 weeks washout period for all groups. Blood was collected at 3, 7, and 60 days in acute experiment, while, they were collected only before and  after  2  months  in  chronic  experiment.  Acute  and  chronic  administration  of  GNPs  (10  or 50 nm size) in male albino rats induced no significant alterations for liver and kidney functions, lipid profile parameters and different haematological parameters at days 3 and 60 of the study. However, on day-7 post-treatment, GNPs-treated rats showed significantly (P P <0.05) decreased serum glucose levels. In conclusion acute or chronic administration of 10 nm or 50 nm GNPs could alter the liver, kidney functions and blood profile on day 7 post-treatment, however, these values returned to the normal levels on day 60 post- injection. Also, the chronic administration of GNPs induced a hypoglycemic effect in male albino rats

ICAR: endoscopic skull‐base surgery

n/

Adenosine role in brain functions : pathophysiological influence on Parkinson's disease and other brain disorders

Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters(e.g., dopamine). In this review, we highlight the role of adenosine in behavior as well as its interaction with other neurotransmitters, such as dopamine. We also discuss brain disorders impacted by alterations to adenosine, and how targeting adenosine can ameliorate Parkinson’s disease motor symptoms. We also discuss the role of caffeine (as an adenosine antagonist) on cognition as well as a neuroprotective agent against Parkinson’s disease (PD)

Dose-dependent neuroprotective effect of caffeine on a rotenone-induced rat model of Parkinsonism : a histological study

Several lines of evidence have demonstrated an inverse relationship between caffeine utilization and Parkinson's disease (PD) progression. Caffeine is a methylxanthine known as a non-specific inhibitor of adenosine (A2A and A1) receptors in the cerebrum and demonstrated to be a neuroprotective medication. In this study, the neuroprotective efficacy of two different doses of caffeine ranging above the usual consumption dose and below the toxic dose was investigated using histopathological and immunohistochemical methods. Thirty-two male rats were randomly divided into 4 groups, with 8 in each group: vehicle control (1 ml/kg/48 h for 12 days), rotenone (1.5 mg/kg/48 h, s.c. for 12 days), low-dose Caffeine-treated: (10 mg/kg IP. daily for 12 days), high-dose Caffeine-treated (20 mg IP daily for 12 days). Twenty-four hours after the last rotenone injection, animals were sacrificed and brains were sectioned and prepared for histopathological staining with hematoxylinand eosin, cresyl violet and Mallory's phosphotungestic acid haematoxylinand for immunohistochemical staining of tyrosine hydroxylase. Our study showed that the treatment with caffeine improved histopathological degeneration in the substantia nigra parts compacta (SNpc) neurons and hindered the reduction in dopamine concentration caused by rotenone. We also found that a higher dose of caffeine was more effective against histopathological degeneration. These results suggest that caffeine has a dose-dependent neuroprotective effect